HCV variants with reduced sensitivity to telaprevir were observed in the majority of patients in whom HCV RNA didn’t become undetectable, like the previously explained variants with NS3/4A positions 36, 54, 155, and 156.9 Follow-up of patients without a sustained virologic response demonstrated that 55 percent of those with resistant variants at the time of treatment failure no longer experienced them at their last visit . Safety and Side-Effect Profile In the entire treatment phase, 9 percent of patients had serious adverse events, anemia being the most typical, reported in 2 percent of patients . A complete of 2 percent of patients in the T12PR24 group, in comparison with 10 percent of the patients in the T12PR48 group who had had an extended rapid virologic response, had severe adverse events .Permuted-block randomization was used, with stratification relating to medical site and regarding to whether the patient was a candidate for SVR, for medical therapy by itself, or for both . The resulting trial included two main components. Patients in the Hypothesis 1 element were randomly assigned to get either medical therapy only or medical therapy plus CABG. The Hypothesis 1 element of the trial is normally ongoing. Sufferers in the Hypothesis 2 component were randomly assigned to get either medical therapy plus CABG or medical therapy plus CABG and medical ventricular reconstruction.